Interleukin-18 restores immune suppression in patients with nonseptic surgery, but not with sepsis.
BACKGROUND
We investigated cellular immune responses, in particular interferon gamma (IFN-gamma) production, by peripheral blood mononuclear cells (PBMCs) in patients with septic and nonseptic surgical stress, focusing on interleukin (IL)-18 and its receptor (IL-18R).


METHODS
Thirty-two patients with alimentary tract carcinoma who underwent elective surgery (OP) and 26 septic patients (SP) with peritonitis were enrolled in this study. Blood was collected on the first postoperative day (POD1), POD5, POD10, and POD15 in the OP group and on the emergency admission in the SP group. Ten healthy volunteers served as controls. PBMCs were cultured in the presence of anti-CD3 antibody or IL-2 and IL-12, with or without additional IL-18 stimulation, to measure IFN-gamma production. IL-18R expression on CD56+ NK (natural killer) cells was evaluated by flow cytometry.


RESULTS
IL-2- and IL-12-induced IFN-gamma production by PBMCs was suppressed significantly in both the OP (POD5) and SP groups compared with that in healthy controls. Interestingly, additional IL-18 stimulation up-regulated IFN-gamma production by PBMCs in the OP group as well as the control group, but not in the SP group. IL-18R expression on CD56+ NK cells was maintained consistently in the OP group as well as the control group, but decreased in the SP group.


CONCLUSIONS
IFN-gamma production induced by cytokines (IL-2 and IL-12) was suppressed in PBMCs from both patients with sepsis and those who had undergone elective surgery. However, IL-18R expression on CD56+ NK cells was different between patients with sepsis and nonseptic surgical stress. Our results suggest that exogenous IL-18 administration may be effective in preventing immune suppression in patients with nonseptic elective surgery.
Hiraki
Shuhichi
S
Department of Surgery, National Defense Medical College, Namiki 3-2, Tokorozawa, Saitama 359-8513, Japan.
Ono
Satoshi
S
Kinoshita
Manabu
M
Tsujimoto
Hironori
H
Seki
Shuhji
S
Mochizuki
Hidetaka
H
D019002:CD56 Antigen / Q000276:immunology; D002478:Cells, Cultured; D004067:Digestive System Neoplasms / Q000097:blood / Q000276:immunology / Q000601:surgery; D013505:Digestive System Surgical Procedures / Q000379:methods; D017558:Elective Surgical Procedures; D005434:Flow Cytometry; D006801:Humans; D007111:Immunity, Cellular / Q000502:physiology*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000097:blood; D018664:Interleukin-12 / Q000097:blood; D020382:Interleukin-18 / Q000097:blood* / Q000276:immunology; D007376:Interleukin-2 / Q000097:blood; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D007813:Laparotomy; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000378:metabolism; D011184:Postoperative Period; D011379:Prognosis; D053724:Receptors, Interleukin-18 / Q000096:biosynthesis / Q000097:blood / Q000276:immunology; D012189:Retrospective Studies; D018805:Sepsis / Q000097:blood / Q000276:immunology; D012773:Shock, Surgical / Q000097:blood / Q000276:immunology*
D019002:CD56 Antigen; D020382:Interleukin-18; D007376:Interleukin-2; D053724:Receptors, Interleukin-18; D018664:Interleukin-12; D007371:Interferon-gamma